Articles with public access mandates - Daniel CatenacciLearn more
Available somewhere: 70
Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial
CS Fuchs, T Doi, RW Jang, K Muro, T Satoh, M Machado, W Sun, SI Jalal, ...
JAMA oncology 4 (5), e180013-e180013, 2018
Mandates: US National Institutes of Health
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
GK Abou-Alfa, V Sahai, A Hollebecque, G Vaccaro, D Melisi, R Al-Rajabi, ...
The Lancet Oncology 21 (5), 671-684, 2020
Mandates: US National Institutes of Health
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
GK Abou-Alfa, T Macarulla, MM Javle, RK Kelley, SJ Lubner, J Adeva, ...
The Lancet Oncology 21 (6), 796-807, 2020
Mandates: US National Institutes of Health
Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer
DVT Catenacci, MR Junttila, T Karrison, N Bahary, MN Horiba, SR Nattam, ...
Journal of Clinical Oncology 33 (36), 4284-4292, 2015
Mandates: US National Institutes of Health
New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing
JS Ross, K Wang, L Gay, R Al-Rohil, JV Rand, DM Jones, HJ Lee, ...
The oncologist 19 (3), 235-242, 2014
Mandates: US National Institutes of Health
Extremely high genetic diversity in a single tumor points to prevalence of non-Darwinian cell evolution
S Ling, Z Hu, Z Yang, F Yang, Y Li, P Lin, K Chen, L Dong, L Cao, Y Tao, ...
Proceedings of the National Academy of Sciences 112 (47), E6496-E6505, 2015
Mandates: US National Institutes of Health, Chinese Academy of Sciences, National …
Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised …
DVT Catenacci, NC Tebbutt, I Davidenko, AM Murad, SE Al-Batran, ...
The lancet oncology 18 (11), 1467-1482, 2017
Mandates: US National Institutes of Health
Assessment of pembrolizumab therapy for the treatment of microsatellite instability–high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE …
J Chao, CS Fuchs, K Shitara, J Tabernero, K Muro, E Van Cutsem, ...
JAMA oncology 7 (6), 895-902, 2021
Mandates: US National Institutes of Health
Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial
AX Zhu, T Macarulla, MM Javle, RK Kelley, SJ Lubner, J Adeva, ...
JAMA oncology 7 (11), 1669-1677, 2021
Mandates: US National Institutes of Health
Genomic heterogeneity as a barrier to precision medicine in gastroesophageal adenocarcinoma
E Pectasides, MD Stachler, S Derks, Y Liu, S Maron, M Islam, L Alpert, ...
Cancer discovery 8 (1), 37-48, 2018
Mandates: US National Institutes of Health
Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition
GS Wong, J Zhou, JB Liu, Z Wu, X Xu, T Li, D Xu, SE Schumacher, ...
Nature medicine 24 (7), 968-977, 2018
Mandates: US National Institutes of Health
Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer
MA Shah, ZA Wainberg, DVT Catenacci, HS Hochster, J Ford, P Kunz, ...
PloS one 8 (3), e54014, 2013
Mandates: US National Institutes of Health
A phase I study of FOLFIRINOX plus IPI-926, a hedgehog pathway inhibitor, for advanced pancreatic adenocarcinoma
AH Ko, N LoConte, MA Tempero, EJ Walker, RK Kelley, S Lewis, ...
Pancreas 45 (3), 370-375, 2016
Mandates: US National Institutes of Health
Circulating tumor DNA sequencing analysis of gastroesophageal adenocarcinoma
SB Maron, LM Chase, S Lomnicki, S Kochanny, KL Moore, SS Joshi, ...
Clinical cancer research 25 (23), 7098-7112, 2019
Mandates: US National Institutes of Health
Next-generation clinical trials: novel strategies to address the challenge of tumor molecular heterogeneity
DVT Catenacci
Molecular oncology 9 (5), 967-996, 2015
Mandates: US National Institutes of Health
Acquisition of portal venous circulating tumor cells from patients with pancreaticobiliary cancers by endoscopic ultrasound
DVT Catenacci, CG Chapman, P Xu, A Koons, VJ Konda, UD Siddiqui, ...
Gastroenterology 149 (7), 1794-1803. e4, 2015
Mandates: US National Institutes of Health
Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence
DVT Catenacci, L Henderson, SY Xiao, P Patel, RL Yauch, P Hegde, ...
Cancer discovery 1 (7), 573-579, 2011
Mandates: US National Institutes of Health
Spatial and temporal heterogeneity of PD-L1 expression and tumor mutational burden in gastroesophageal adenocarcinoma at baseline diagnosis and after chemotherapy
KI Zhou, B Peterson, A Serritella, J Thomas, N Reizine, S Moya, C Tan, ...
Clinical Cancer Research 26 (24), 6453-6463, 2020
Mandates: US National Institutes of Health
Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma
SB Maron, L Alpert, HA Kwak, S Lomnicki, L Chase, D Xu, E O'Day, ...
Cancer discovery 8 (6), 696-713, 2018
Mandates: US National Institutes of Health
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma
DVT Catenacci, G Cervantes, S Yala, EA Nelson, E El-Hashani, R Kanteti, ...
Cancer biology & therapy 12 (1), 9-46, 2011
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program